ATE248217T1 - Nährmedium für cho-zellen und daran angepasste zellen - Google Patents

Nährmedium für cho-zellen und daran angepasste zellen

Info

Publication number
ATE248217T1
ATE248217T1 AT91309596T AT91309596T ATE248217T1 AT E248217 T1 ATE248217 T1 AT E248217T1 AT 91309596 T AT91309596 T AT 91309596T AT 91309596 T AT91309596 T AT 91309596T AT E248217 T1 ATE248217 T1 AT E248217T1
Authority
AT
Austria
Prior art keywords
cells
cho
culture medium
adaptable
source
Prior art date
Application number
AT91309596T
Other languages
English (en)
Inventor
Michael John Keen
Nicholas Timothy Rapson
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10683864&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE248217(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wellcome Found filed Critical Wellcome Found
Application granted granted Critical
Publication of ATE248217T1 publication Critical patent/ATE248217T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0043—Medium free of human- or animal-derived components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/34—Sugars
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/36—Lipids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/74—Undefined extracts from fungi, e.g. yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/76—Undefined extracts from plants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/135—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/33—Insulin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones
    • C12N2501/392—Sexual steroids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/395—Thyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Materials For Medical Uses (AREA)
  • Liquid Crystal (AREA)
AT91309596T 1990-10-17 1991-10-17 Nährmedium für cho-zellen und daran angepasste zellen ATE248217T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9022545A GB9022545D0 (en) 1990-10-17 1990-10-17 Culture medium

Publications (1)

Publication Number Publication Date
ATE248217T1 true ATE248217T1 (de) 2003-09-15

Family

ID=10683864

Family Applications (2)

Application Number Title Priority Date Filing Date
AT02003143T ATE382680T1 (de) 1990-10-17 1991-10-17 Nährmedium für cho-zellen und daran angepasste zellen
AT91309596T ATE248217T1 (de) 1990-10-17 1991-10-17 Nährmedium für cho-zellen und daran angepasste zellen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT02003143T ATE382680T1 (de) 1990-10-17 1991-10-17 Nährmedium für cho-zellen und daran angepasste zellen

Country Status (13)

Country Link
US (4) US5316938A (de)
EP (3) EP1849862A3 (de)
JP (1) JP2625302B2 (de)
AT (2) ATE382680T1 (de)
AU (1) AU645615B2 (de)
CA (1) CA2053586C (de)
DE (2) DE69133303T2 (de)
DK (2) DK0481791T3 (de)
ES (2) ES2298301T3 (de)
GB (1) GB9022545D0 (de)
IE (1) IE913559A1 (de)
NZ (1) NZ240248A (de)
ZA (1) ZA918249B (de)

Families Citing this family (209)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5292655A (en) * 1990-01-29 1994-03-08 Wille Jr John J Method for the formation of a histologically-complete skin substitute
GB9022543D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Antibody production
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
JPH0789908B2 (ja) * 1991-02-28 1995-10-04 倉敷紡績株式会社 動物細胞培養用無血清培地
DE4115722A1 (de) * 1991-05-14 1992-11-19 Boehringer Mannheim Gmbh Serumfreies medium zur kultivierung von saeugerzellen
GB9118664D0 (en) * 1991-08-30 1991-10-16 Celltech Ltd Cell culture
US6352707B1 (en) 1992-02-24 2002-03-05 Anton-Lewis Usala Transplant encapsulation in a hydrogel matrix to obscure immune recognition
US6231881B1 (en) 1992-02-24 2001-05-15 Anton-Lewis Usala Medium and matrix for long-term proliferation of cells
IL102929A (en) * 1992-08-24 1996-11-14 Interpharm Lab Ltd Serum-free medium for mammalian cells
DE4313620A1 (de) * 1993-04-26 1994-10-27 Biotechnolog Forschung Gmbh Hamsterzellinien und Verfahren zur Glykoproteingewinnung
USH1532H (en) * 1993-11-03 1996-05-07 Genetics Institute, Inc. Adaption of mammalian cell lines to high cell densities
EP0653487A1 (de) * 1993-11-07 1995-05-17 Ferruccio Dr. Messi Serum- und proteinfrei wachsende Zellen
US5856179A (en) * 1994-03-10 1999-01-05 Genentech, Inc. Polypeptide production in animal cell culture
US5512477A (en) * 1994-04-21 1996-04-30 Genzyme Corporation Serum-free medium supplement
US5753489A (en) * 1994-11-10 1998-05-19 Immuno Ag Method for producing viruses and vaccines in serum-free culture
US5756341A (en) * 1994-11-10 1998-05-26 Immuno Ag Method for controlling the infectivity of viruses
US6146873A (en) * 1994-11-10 2000-11-14 Baxter Aktiengesellschaft Production of orthomyxoviruses in monkey kidney cells using protein-free media
US5698433A (en) * 1994-11-10 1997-12-16 Immuno Ag Method for producing influenza virus and vaccine
US5705364A (en) * 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
US6656466B1 (en) * 1995-06-06 2003-12-02 Genetech, Inc. Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition
US5721121A (en) * 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
EP0891419A4 (de) * 1996-03-12 2000-03-01 Life Technologies Inc Nährstoffzusatz für hematopoetische zellkulturen
WO1997038090A1 (en) * 1996-04-09 1997-10-16 Board Of The Trustees Of Southern Illinois University A cultural medium for maintaining neural cells in ambient atmosphere
JP2000517188A (ja) 1996-08-30 2000-12-26 ライフ テクノロジーズ，インコーポレイテッド 無血清哺乳動物細胞培養培地およびその使用
JP4543402B2 (ja) * 1996-10-10 2010-09-15 ライフ テクノロジーズ コーポレーション 植物由来栄養素を含む動物細胞培養培地
US20040171152A1 (en) * 1996-10-10 2004-09-02 Invitrogen Corporation Animal cell culture media comprising non-animal or plant-derived nutrients
US6692961B1 (en) * 1996-10-11 2004-02-17 Invitrogen Corporation Defined systems for epithelial cell culture and use thereof
US20020012991A1 (en) * 1997-04-07 2002-01-31 Florence Chua Nee Ho Kit Fong Cell culture media for enhanced protein production
US6475725B1 (en) * 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
US6989264B2 (en) 1997-09-05 2006-01-24 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6566118B1 (en) * 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
WO1999057246A1 (en) * 1998-05-01 1999-11-11 Life Technologies, Inc. Animal cell culture media comprising non-animal or plant-derived nutrients
US6528286B1 (en) * 1998-05-29 2003-03-04 Genentech, Inc. Mammalian cell culture process for producing glycoproteins
US6406909B1 (en) * 1998-07-10 2002-06-18 Chugai Seiyaku Kabushiki Kaisha Serum-free medium for culturing animal cells
US7294481B1 (en) * 1999-01-05 2007-11-13 Immunex Corporation Method for producing recombinant proteins
EP2275540B1 (de) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Verfahren zur Steuerung der Aktivität von immunologisch funktionellen Molekülen
US20060286668A1 (en) * 1999-04-30 2006-12-21 Invitrogen Corporation Animal-cell culture media comprising non-animal or plant-derived nutrients
AT409379B (de) * 1999-06-02 2002-07-25 Baxter Ag Medium zur protein- und serumfreien kultivierung von zellen
PE20010288A1 (es) 1999-07-02 2001-03-07 Hoffmann La Roche Derivados de eritropoyetina
JP2003506077A (ja) * 1999-08-05 2003-02-18 バクスター アクチェンゲゼルシャフト 組換え安定細胞クローン、その産生およびその使用
JP4668498B2 (ja) 1999-10-19 2011-04-13 協和発酵キリン株式会社 ポリペプチドの製造方法
KR20010056451A (ko) * 1999-12-15 2001-07-04 윤재승 아르기닌이 강화된 동물세포 배양용 배지 조성물
US6811776B2 (en) 2000-12-27 2004-11-02 The Regents Of The University Of Michigan Process for ex vivo formation of mammalian bone and uses thereof
EP1364002A2 (de) * 2000-08-23 2003-11-26 Pfizer Products Inc. Verfahren zur herstellung des neutrophilen hemmfaktors
US20020099183A1 (en) * 2000-08-23 2002-07-25 Pluschkell Stefanie Beate Process for the preparation of neutrophil inhibitory factor
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
BR0116381A (pt) 2000-12-20 2004-02-25 Hoffmann La Roche Conjugado, composição farmacêutica que compreende o mesmo e sua utilização, processo para o tratamento profilático e/ou terapêutico de distúrbios, processo para a preparação de um conjugado, compostos e glicoproteìnas de eritropoetina
US6506576B2 (en) 2001-03-14 2003-01-14 Board Of Trustees Of The University Of Arkansas Serum-and steroid-free culture media for cerebellar granule neurons
KR20040065231A (ko) * 2001-11-28 2004-07-21 산도즈 게엠베하 세포 배양 방법
US20070148171A1 (en) * 2002-09-27 2007-06-28 Xencor, Inc. Optimized anti-CD30 antibodies
US7662925B2 (en) * 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US20080260731A1 (en) * 2002-03-01 2008-10-23 Bernett Matthew J Optimized antibodies that target cd19
US20080254027A1 (en) * 2002-03-01 2008-10-16 Bernett Matthew J Optimized CD5 antibodies and methods of using the same
US7691568B2 (en) 2002-04-09 2010-04-06 Kyowa Hakko Kirin Co., Ltd Antibody composition-containing medicament
EP2287288B1 (de) 2002-07-09 2012-11-07 Baxter International Inc. Tierproteinfreies Zellkulturmedium
US7067279B1 (en) 2002-08-23 2006-06-27 Immunex Corporation Cell culture performance with betaine
US20060235208A1 (en) * 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
EP1551869A2 (de) 2002-10-15 2005-07-13 Intercell AG Bindungdsfaktoren von gruppe b-streptococcus, dafür kodierende nukleinsäuren und verwendungen davon
DE10255508A1 (de) * 2002-11-27 2004-06-17 Forschungszentrum Jülich GmbH Verfahren zur Kultivierung von Zellen zur Produktion von Substanzen
CN100402660C (zh) † 2002-12-23 2008-07-16 布里斯托尔-迈尔斯斯奎布公司 用于蛋白质生产的哺乳动物细胞培养方法中产物质量提高
GB0304799D0 (en) 2003-03-03 2003-04-09 Glaxosmithkline Biolog Sa Novel method
US8388955B2 (en) * 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US20070275460A1 (en) * 2003-03-03 2007-11-29 Xencor.Inc. Fc Variants With Optimized Fc Receptor Binding Properties
EP1622941A2 (de) * 2003-03-20 2006-02-08 ImClone Systems Incorporated Methode zur produktion von anti-egfr antikörpern
US9051373B2 (en) 2003-05-02 2015-06-09 Xencor, Inc. Optimized Fc variants
ES2285481T3 (es) * 2003-08-08 2007-11-16 Cambridge Antibody Technology Limited Cultivo de celulas de mieloma en un medio exento de transferrina y bajo en hierro.
GB2404665B (en) * 2003-08-08 2005-07-06 Cambridge Antibody Tech Cell culture
CA2537462A1 (en) * 2003-09-18 2005-03-31 Raven Biotechnologies, Inc. Cell culture media comprising fructose as the primary energy source
US8101720B2 (en) * 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
AU2004280064A1 (en) * 2003-10-09 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Genomically modified cell neutralized to serum-free system
US20070264710A1 (en) * 2003-10-09 2007-11-15 Hyea-Kyung Ahn Process for Purifying Human Thrombopoietin with High Content of Sialic Acid
ES2418830T3 (es) 2003-10-27 2013-08-16 Wyeth Llc Retirada de agregados de alto peso molecular usando cromatografía de hidroxiapatita
WO2005077981A2 (en) * 2003-12-22 2005-08-25 Xencor, Inc. Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
US7255288B2 (en) * 2004-03-08 2007-08-14 Wan Shan Chan Aroma therapy for fountain
EP2053062A1 (de) * 2004-03-24 2009-04-29 Xencor, Inc. Immunoglobinvarianten außerhalb der Fc-Region
US20150010550A1 (en) 2004-07-15 2015-01-08 Xencor, Inc. OPTIMIZED Fc VARIANTS
TWI384069B (zh) 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
TWI374935B (en) 2004-08-27 2012-10-21 Pfizer Ireland Pharmaceuticals Production of α-abeta
TWI364458B (en) 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
WO2006031994A2 (en) * 2004-09-14 2006-03-23 Xencor, Inc. Monomeric immunoglobulin fc domains
US20060094104A1 (en) * 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
AU2011221414B2 (en) * 2004-10-29 2012-09-20 Takeda Pharmaceutical Company Limited Animal Protein-Free Media for Cultivation of Cells
AU2005330353B2 (en) * 2004-11-02 2010-10-14 Ares Trading S.A. Serum-free cell culture medium for mammalian cells
MX2007005210A (es) * 2004-11-02 2007-05-11 Ares Trading Sa Medio de cultivo de celula libre de suero para las celulas de los mamiferos.
US8273553B2 (en) * 2004-11-02 2012-09-25 Ares Trading S.A. Production of growth hormone in serum-free cell culture medium for mammalian cells
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US8802820B2 (en) * 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US8367805B2 (en) * 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
EP2845865A1 (de) * 2004-11-12 2015-03-11 Xencor Inc. FC-Varianten mit Veränderter Bindung zu FCRN
US20070135620A1 (en) * 2004-11-12 2007-06-14 Xencor, Inc. Fc variants with altered binding to FcRn
WO2006076594A2 (en) * 2005-01-12 2006-07-20 Xencor, Inc. Antibodies and fc fusion proteins with altered immunogenicity
EP1851305B1 (de) * 2005-02-11 2012-01-18 Novo Nordisk Health Care AG Herstellung eines proteins in serumfreier zellkultur, die ein proteinhydrolysat aus pflanzen enthält
JP2006310392A (ja) * 2005-04-26 2006-11-09 Toshiba Corp 電子ビーム描画方法及び電子ビーム描画装置
CA2610315A1 (en) * 2005-06-03 2006-12-07 Biovitrum Ab (Publ) Process for cultivating animal cells comprising the feeding of plant-derived peptones
TWI369401B (en) * 2005-07-05 2012-08-01 Ares Trading Sa Serum-free culture medium for the production of recombinant gonadotropins
AU2006299429B2 (en) * 2005-10-03 2012-02-23 Xencor, Inc. Fc variants with optimized Fc receptor binding properties
CA2625998C (en) 2005-10-06 2015-12-01 Xencor, Inc. Optimized anti-cd30 antibodies
EP1974014B1 (de) 2006-01-04 2017-04-19 Baxalta Incorporated Oligopeptid-freie zellkulturmedien
US20070190057A1 (en) 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
KR101495549B1 (ko) 2006-07-13 2015-02-25 와이어쓰 엘엘씨 당단백질의 생산
US8765924B2 (en) 2006-08-04 2014-07-01 Prolong Pharmaceuticals, Inc. Modified erythropoietin
AU2007285976B2 (en) * 2006-08-14 2011-08-18 Xencor, Inc Optimized antibodies that target CD19
NZ575328A (en) 2006-09-13 2012-06-29 Abbott Lab Cell culture improvements
EP2500415A1 (de) * 2006-09-13 2012-09-19 Abbott Laboratories Verbesserungen an Zellkulturen
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
WO2008036688A2 (en) * 2006-09-18 2008-03-27 Xencor, Inc. Optimized antibodies that target hm1.24
BRPI0810472A2 (pt) 2007-04-16 2014-11-11 Momenta Pharmaceuticals Inc Métodos relacionados à glicosilação da superfície celular
EP2135093B1 (de) * 2007-04-16 2015-04-15 Momenta Pharmaceuticals, Inc. Analyse phosphorylierter glycane, glycopeptide oder glycoproteine durch imac
WO2008128219A1 (en) 2007-04-16 2008-10-23 Momenta Pharmaceuticals, Inc. Comparative analysis of protein conformations by using 2d noesy nmr spectra
TW200902708A (en) 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
WO2008136398A1 (ja) * 2007-04-26 2008-11-13 Chugai Seiyaku Kabushiki Kaisha 高濃度アミノ酸含有培地を用いた細胞の培養方法
GB0710614D0 (en) * 2007-06-04 2007-07-11 Lonza Biologics Plc Mammalian expression vector with a highly efficient secretory signal sequence
CN101319200B (zh) * 2007-06-08 2010-05-19 中国科学院大连化学物理研究所 一种适用于微囊化cho细胞的无血清培养基及其应用
WO2008154014A2 (en) * 2007-06-11 2008-12-18 Amgen Inc. A method for culturing mammalian cells to improve recombinant protein production
US7580304B2 (en) * 2007-06-15 2009-08-25 United Memories, Inc. Multiple bus charge sharing
EP2188371B1 (de) * 2007-08-09 2017-12-20 Wyeth LLC Verwendung von perfusion zur erhöhung der produktion von fed-batch-zellkulturen in bioreaktoren
PL2592148T3 (pl) * 2007-10-12 2019-01-31 F. Hoffmann-La Roche Ag Ekspresja białka z wielu kwasów nukleinowych
HUE024903T2 (en) 2007-12-26 2016-02-29 Xencor Inc FC variants with modified binding to FCRN
PL2235197T3 (pl) * 2007-12-27 2018-01-31 Baxalta GmbH Sposoby hodowli komórek
DK2250251T3 (en) 2008-01-09 2018-01-22 Sartorius Stedim Cellca Gmbh Improved culture medium additive and method of using it
US20110014624A1 (en) * 2008-03-12 2011-01-20 Wyeth Llc Methods For Identifying Cells Suitable For Large-Scale Production of Recombinant Proteins
EP2345713A4 (de) * 2008-04-18 2012-07-11 Shanghai Nat Engineering Res Ct Of Antibody Medicine Co Ltd Konzentrierte kulturlösung und anwendungsverfahren dafür
DE102008002210A1 (de) 2008-06-04 2009-12-10 Evonik Degussa Gmbh Verfahren zur fermentativen Herstellung von Erythropoietin
ES2699434T3 (es) * 2008-10-31 2019-02-11 Wyeth Llc Purificación de proteínas ácidas utilizando cromatografía de hidroxiapatita cerámica
EP2977461A1 (de) * 2008-11-12 2016-01-27 Baxalta Incorporated Verfahren zur herstellung von serumfreiem, insulinfreiem faktor vii
EP2379710A1 (de) * 2008-12-19 2011-10-26 Schering Corporation Futterzusatz für die säugerzellkultur und verwendungsverfahren
EP2358731B1 (de) 2008-12-19 2016-03-09 Momenta Pharmaceuticals, Inc. Verfahren bezüglich modifizierter glykane
JP5764068B2 (ja) 2008-12-30 2015-08-12 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ アルキル−アミン−ｎ−オキシド（ＡＡＮＯｘ）を用いる細胞増殖を増強する方法
RU2551229C2 (ru) * 2009-02-27 2015-05-20 Новартис Аг Способы селекции эукариотических клеток, экспрессирующих гетерологичный белок
US8597943B2 (en) 2009-04-09 2013-12-03 Cellca Gmbh Method for improved single cell cloning
IL256966B2 (en) 2009-07-10 2023-12-01 O Scott Linzy Iii Methods and compositions for the treatment of diseases related to the thyroid gland, with a reduced amount of folates
SG178194A1 (en) 2009-07-31 2012-03-29 Baxter Int Cell culture medium for adamts protein expression
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
EP2480569B1 (de) 2009-09-23 2016-04-13 ratiopharm GmbH Verfahren zur reinigung von rekombinantem humanem erythropoietin (epo)
BR122022001178B1 (pt) 2009-10-26 2022-10-04 F. Hoffmann-La Roche Ag Método para a produção de uma imunoglobulina glicosilada e seu uso
EP2516624B1 (de) 2009-12-23 2020-02-05 Merck Sharp & Dohme Corp. Zelllinie 3m
US8362210B2 (en) 2010-01-19 2013-01-29 Xencor, Inc. Antibody variants with enhanced complement activity
DK2563904T3 (en) 2010-04-26 2015-04-07 Novartis Ag Improved cell culture medium
PT3330370T (pt) 2010-04-26 2021-05-11 Novartis Ag Processo para cultivo de células cho
CN102234627B (zh) * 2010-04-30 2015-06-03 中国科学院广州生物医药与健康研究院 一种培养基添加剂及其应用
ES2761692T5 (es) 2010-07-08 2023-07-05 Takeda Pharmaceuticals Co Método de producción de vWF recombinante de alto peso molecular en cultivo celular
EP2601287B1 (de) 2010-08-05 2015-01-07 Amgen Inc. Dipeptide zur erhöhung des ertrags und der lebensfähigkeit von zellkulturen
ES2710543T3 (es) * 2010-12-27 2019-04-25 Kyowa Hakko Kirin Co Ltd Método para preparar una disolución acuosa que contiene medio de cultivo y agente quelante
US9133493B2 (en) 2011-04-21 2015-09-15 Amgen Inc. Method for culturing mammalian cells to improve recombinant protein production
EP2702077A2 (de) 2011-04-27 2014-03-05 AbbVie Inc. Verfahren zur steuerung des galactosylierungsprofil von rekombinant exprimierten proteinen
DK2702164T3 (en) 2011-04-29 2016-02-01 Biocon Res Ltd METHOD FOR REDUCING heterogeneity OF ANTIBODIES AND METHOD OF PRODUCING THESE ANTIBODIES
JP6104242B2 (ja) 2011-07-12 2017-03-29 フードチェク・システムズ・インコーポレイテッドＦｏｏｄｃｈｅｋ Ｓｙｓｔｅｍｓ， Ｉｎｃ． サルモネラおよび大腸菌を培養するための培養培地、方法、ならびにサルモネラおよび大腸菌を検出するための方法
AU2012283715B2 (en) 2011-07-13 2015-09-17 Foodchek Systems, Inc. Culture medium, method for culturing Listeria, and method for detecting Listeria
KR20170021919A (ko) 2011-10-21 2017-02-28 화이자 인코포레이티드 철을 첨가하여 세포 배양을 개선하는 방법
WO2013126813A1 (en) 2012-02-22 2013-08-29 Amgen Inc. Autologous mammalian models derived from induced pluripotent stem cells and related methods
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
CA2883272A1 (en) 2012-09-02 2014-03-06 Abbvie Inc. Methods to control protein heterogeneity
EP2711426B1 (de) 2012-09-24 2015-04-08 Lonza Biologics plc Expressionsvektoren mit chimärem Cytomegalieviruspromotor und Verstärkersequenzen
CA2905010A1 (en) 2013-03-12 2014-09-18 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
ITTO20130493A1 (it) * 2013-06-14 2014-12-15 Determinants Of Metabolism Res Lab S R L Composizione per l'eliminazione di animali molesti infestanti
JP6195191B2 (ja) * 2013-08-08 2017-09-13 極東製薬工業株式会社 無タンパク質・無脂質培地馴化細胞株を用いた組換えタンパク質の製造方法
JP6190205B2 (ja) * 2013-08-08 2017-08-30 極東製薬工業株式会社 無タンパク質・無脂質培地馴化細胞株、その製造方法及び培地
US11078464B2 (en) 2013-08-30 2021-08-03 Amgen Inc. High titer recombinant AAV vector production in adherent and suspension cells
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
US10634665B2 (en) 2014-09-24 2020-04-28 Triad National Security, Llc Bio-assessment device and method of making the device
MX2017004769A (es) 2014-10-15 2017-10-16 Amgen Inc Elementos promotores y reguladores para mejorar la expresion de genes heterologos en celulas hospederas.
JP6432774B2 (ja) * 2014-12-25 2018-12-05 江南化工株式会社 細胞賦活剤
KR20180093086A (ko) 2016-01-06 2018-08-20 론자 리미티드 개선된 생산을 위한 단백질 분해의 억제
US10119117B2 (en) 2016-01-28 2018-11-06 Nanogen Pharmaceutical Biotechnology Co., Ltd Universal, glycosylation enhancer, completely chemically defined medium formulation
WO2017146646A1 (en) * 2016-02-22 2017-08-31 Agency For Science, Technology And Research Cell culture medium
US11236520B2 (en) 2016-03-10 2022-02-01 Lonza Ltd Customizable facility
US10689873B2 (en) 2016-03-10 2020-06-23 Lonza Ltd Customizable facility
EP3443348A1 (de) 2016-04-14 2019-02-20 Lonza Ltd Zusammensetzungen und verfahren zur detektion von wirtszellenproteinen
TW202140776A (zh) * 2016-04-26 2021-11-01 美商美國泰福生技股份有限公司 細胞培養基
AU2017259010B2 (en) 2016-05-03 2021-04-22 Lonza Ltd Modulation of lipid metabolism for protein production
KR102451374B1 (ko) 2016-06-10 2022-10-11 론자 리미티드 단백질을 안정화시키는 방법
IL307217A (en) 2016-08-02 2023-11-01 Lonza Ag Customizable facility
WO2018031858A1 (en) 2016-08-12 2018-02-15 Lonza Ltd Proteomic analysis of host cell proteins
EP3512545B1 (de) 2016-09-16 2022-10-26 Leukocare AG Neuartiges verfahren zur stabilisierung eines biopharmazeutischen arzneimittelprodukts während der verarbeitung
CN106635958A (zh) * 2016-12-24 2017-05-10 严志海 一种中国仓鼠卵巢细胞培养基
SG11201908127WA (en) 2017-03-10 2019-10-30 Hoffmann La Roche Method for producing multispecific antibodies
CN110785494A (zh) 2017-06-16 2020-02-11 隆萨有限公司 用于生产生物制品的通用自调节哺乳动物细胞系平台
US20200255785A1 (en) 2017-09-15 2020-08-13 Bristol-Myers Squibb Company Online biomass capacitance monitoring during large scale production of polypeptides of interest
AU2018381301A1 (en) 2017-12-05 2020-06-11 Lonza Ltd Methods of assaying tropolone
US20230174971A1 (en) 2018-02-02 2023-06-08 Lonza Ltd Methods of cell selection and modifying cell metabolism
WO2019178489A1 (en) 2018-03-16 2019-09-19 Bristol-Myers Squibb Company Metabolic enzyme activity and disulfide bond reduction during protein production
US20190367858A1 (en) 2018-06-01 2019-12-05 Lonza Ltd. Midscale Model For Organic Growth and Phasing
JP2021530225A (ja) 2018-07-13 2021-11-11 ロンザ リミテッドLonza Limited 内因性タンパク質のレベルを低下させることによって生物学的産物の産生を改善する方法
WO2020028616A1 (en) 2018-08-02 2020-02-06 Lonza Ltd Methods for manufacturing recombinant protein comprising a disulfide bond
CN110343666B (zh) * 2019-07-10 2023-05-30 通化东宝药业股份有限公司 一种cho细胞培养的补料培养基及其制备方法和应用
JP2023502916A (ja) 2019-11-14 2023-01-26 ロンザ リミテッド 細胞の選択方法
MY190626A (en) 2019-12-06 2022-04-27 Regeneron Pharma Anti-vegf protein compositions and methods for producing the same
KR20220158052A (ko) * 2020-03-25 2022-11-29 아지노모토 가부시키가이샤 Hepes 함유 배지
US20240083972A1 (en) 2020-12-22 2024-03-14 Amgen Inc. Cell culture method
WO2023045140A1 (zh) * 2021-09-26 2023-03-30 上海迈泰君奥生物技术有限公司 一种提高宿主细胞中抗体表达量的方法
CN113846051B (zh) * 2021-09-28 2023-12-01 无锡多宁生物科技有限公司 一种通用型化学成分限定cho细胞传代培养基及其应用

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE65933C (de) Rheinische Gesellschaft für metall Ventileinrichtung für Spirituskocher
US4205126A (en) 1978-01-01 1980-05-27 Cartaya Oscar A Serum-free cell culture media
MX197183A (es) * 1982-05-05 1994-02-28 Genentech Inc Activador de plasminogeno de tejido humano
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
FR2543158B1 (fr) 1983-03-24 1985-11-15 Inst Nat Sante Rech Med Milieu de culture de cellules animales sans serum, sans hormones et sans facteurs de croissance et procedes de culture primaire et d'obtention de lignees cellulaires utilisant ce milieu
US4767704A (en) * 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4777245A (en) 1984-01-06 1988-10-11 Genelabs Incorporated Non-human primate monoclonal antibodies and methods
EP0164813B1 (de) 1984-06-14 1991-10-09 Teijin Limited Verfahren zur Züchtung tierischer oder pflanzlicher Zellen
JPS6125480A (ja) 1984-07-13 1986-02-04 Nitsusui Seiyaku Kk 細胞用の無血清合成培地
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
GB8531925D0 (en) 1985-12-31 1986-02-05 Bass Plc Propagation of yeast
GB8607679D0 (en) * 1986-03-27 1986-04-30 Winter G P Recombinant dna product
CA1297434C (en) 1986-04-14 1992-03-17 Kenji Murakami Method of producing peptides, recombinant plasmid for use in the same and animal cells transformed with the same
US4677704A (en) * 1986-04-22 1987-07-07 Huggins Richard A Cleaning system for static charged semiconductor wafer surface
EP0248656B1 (de) 1986-06-04 1993-03-31 Director-General of the Agency of Industrial Science and Technology Zubereitung für Zellkultur und ihre Verwendung
JPS637780A (ja) 1986-06-28 1988-01-13 Nippon Zenyaku Kogyo Kk 細胞への鉄供給方法
DE3787805T2 (de) * 1986-08-04 1994-02-10 Univ New South Wales Kensingto Serumfreies gewebekulturmedium, das ein polymerzellenschutzmittel enthält.
CS262822B1 (en) 1986-10-03 1989-04-14 Kovar Jan Synthetic medium for the cultivation of myelomic cells
US5045468A (en) 1986-12-12 1991-09-03 Cell Enterprises, Inc. Protein-free culture medium which promotes hybridoma growth
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP2749011B2 (ja) 1987-02-05 1998-05-13 鐘淵化学工業 株式会社 無血清培地で増殖継代可能な細胞およびその取得方法
JPS63196268A (ja) * 1987-02-10 1988-08-15 Kanegafuchi Chem Ind Co Ltd 無血清培地で継代増殖可能な形質転換細胞、その育種方法およびその細胞による蛋白質の生産方法
EP0283942B1 (de) 1987-03-24 1992-05-20 W.R. Grace & Co.-Conn. Basisnährmedium für eine Zellkultur
CA1341235C (en) 1987-07-24 2001-05-22 Randy R. Robinson Modular assembly of antibody genes, antibodies prepared thereby and use
JP2796547B2 (ja) 1987-09-11 1998-09-10 ジェネンテク，インコーポレイテッド 組換え細胞培養中でのポリペプチド発現の増大法
IL87737A (en) * 1987-09-11 1993-08-18 Genentech Inc Method for culturing polypeptide factor dependent vertebrate recombinant cells
EP0316068A1 (de) * 1987-10-09 1989-05-17 Collaborative Research Inc. Modifizierter Plasminogenaktivator mit niedrigem Molekulargewicht und Verfahren zu seiner Herstellung
NZ226694A (en) 1987-10-28 1994-04-27 Oncogen Human immunoglobulin produced by recombinant dna techniques
DE3801236A1 (de) * 1988-01-18 1989-07-27 Boehringer Mannheim Gmbh Pentosansulfat-medium
US5846534A (en) 1988-02-12 1998-12-08 British Technology Group Limited Antibodies to the antigen campath-1
CA1339198C (en) * 1988-02-12 1997-08-05 Gregory Paul Winter Antibodies to the antigen campath-1
CA1341552C (en) 1988-09-23 2007-10-02 Kenneth Alonso Method of producing human-human hybridomas, the production of monoclonal and polyclonal antibodies therefrom, and therapeutic use thereof
AU4312489A (en) 1988-09-23 1990-04-18 Cetus Corporation Lipid microemulsions for culture media
JPH0322972A (ja) * 1989-01-12 1991-01-31 Ajinomoto Co Inc 無血清培地
IL93463A0 (en) * 1989-02-27 1990-11-29 Lilly Co Eli Improved tissue culture method
US5135866A (en) 1989-03-03 1992-08-04 W. R. Grace & Co.-Conn. Very low protein nutrient medium for cell culture
CA2001550A1 (en) * 1989-03-03 1990-09-03 Aaron H. Heifetz Very low protein nutrient medium for cell culture
GB8905669D0 (en) 1989-03-13 1989-04-26 Celltech Ltd Modified antibodies
AU627591B2 (en) 1989-06-19 1992-08-27 Xoma Corporation Chimeric mouse-human km10 antibody with specificity to a human tumor cell antigen
ATE132907T1 (de) 1989-09-19 1996-01-15 Centocor Inc Verfahren zur verbesserten herstellung von menschlichen antikörpern sowie hierzu benutzte zellen
CA2070182C (en) 1989-12-27 2002-12-24 John Ghrayeb Chimeric immunoglobulin for cd4 receptors
US5122469A (en) * 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
GB9022547D0 (en) 1990-10-17 1990-11-28 Wellcome Found Purified immunoglobulin
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
DE4115722A1 (de) 1991-05-14 1992-11-19 Boehringer Mannheim Gmbh Serumfreies medium zur kultivierung von saeugerzellen
IE922287A1 (en) 1991-07-15 1993-01-27 Wellcome Found Production of antibodies
SK285046B6 (sk) 1991-07-25 2006-05-04 Idec Pharmaceuticals Corporation Chimérna protilátka, ktorá sa špecificky viaže na ľudský antigén, farmaceutický prostriedok s jej obsahom, spôsob jej výroby a použitie
ES2125977T3 (es) 1991-10-15 1999-03-16 Btg Int Ltd Cdw52-anticuerpo especifico para el tratamiento de la inflamacion de las articulaciones mediada por celulas t.
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
AT407255B (de) 1997-06-20 2001-02-26 Immuno Ag Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons
KR20010069066A (ko) 2000-01-12 2001-07-23 이종원 저산소 농도하에서 생존이 가능하도록 하는 동물세포의배양방법
JP2005532415A (ja) 2001-12-11 2005-10-27 メルク　エンド　カムパニー　インコーポレーテッド スタフィロコッカス・アウレウスエキソポリサッカライド及び方法

Also Published As

Publication number Publication date
ES2204885T3 (es) 2004-05-01
EP1221476B1 (de) 2008-01-02
AU8591591A (en) 1992-05-07
EP0481791A2 (de) 1992-04-22
CA2053586C (en) 2003-07-29
NZ240248A (en) 1994-11-25
ZA918249B (en) 1993-04-16
AU645615B2 (en) 1994-01-20
US5316938A (en) 1994-05-31
DE69133589T2 (de) 2009-01-08
GB9022545D0 (en) 1990-11-28
DE69133303T2 (de) 2004-06-24
EP0481791B1 (de) 2003-08-27
DK0481791T3 (da) 2003-12-08
EP0481791A3 (en) 1992-07-08
EP1849862A3 (de) 2008-02-13
ATE382680T1 (de) 2008-01-15
EP1221476A2 (de) 2002-07-10
EP1849862A2 (de) 2007-10-31
US5633162A (en) 1997-05-27
JPH0670757A (ja) 1994-03-15
JP2625302B2 (ja) 1997-07-02
CA2053586A1 (en) 1992-04-18
EP1221476A3 (de) 2003-09-17
DE69133589D1 (de) 2008-02-14
DK1221476T3 (da) 2008-05-13
DE69133303D1 (de) 2003-10-02
ES2298301T3 (es) 2008-05-16
USRE41974E1 (en) 2010-11-30
IE913559A1 (en) 1992-04-22
USRE39792E1 (en) 2007-08-21

Similar Documents

Publication Publication Date Title
ATE382680T1 (de) Nährmedium für cho-zellen und daran angepasste zellen
Azam et al. Cycling of organic matter by bacterioplankton in pelagic marine ecosystems: microenvironmental considerations
PT610474E (pt) Cultura de celulas animais
NZ505330A (en) Low dose artificial insemination sample in which sperm are sorted according to X and Y chromosomes by flow cytometry incorporating a chemically cordinated sheath fluid
IT8820695A0 (it) Metodo per il controllo dell'esatto posizionamento degli oggetti da smistare in un impianto di smistamento automatico.
HK1000074A1 (en) Method to preselect the sex of offspring
MX166885B (es) Metodos de purificacion y reactivacion de proteinas heterologas precipitadas
IL107564A (en) Nucleic acid encoding PstS variants method for production and method for controlling polypeptide production in bacteria transformed by said nucleic acid
PT82500B (pt) Particulas com as propriedades imunogenicas do antigenio hbs e portadoras de um sitio antigenico estranho aos epitopes comportados pelo antigenio hbs, vectores e celulas animais para a producao dessas particulas e composicoes que contem essas particulas para a producao de vacinas mistas
SE8500621L (sv) Forbettrad proteinframstellning med anvendning av hypertoniska medier
Srivastava et al. Enzymatic action of lipoglycoprotein preparations from sperm-acrosomes on rabbit ova
GB2196636B (en) Production of proteins by cell culture
ES2194273T3 (es) Regulacion de la produccion de inmunoglobulinas por la interleucina-9.
CA2286323A1 (en) Cell culture media for enhanced protein production
DE69226350T2 (de) Zellkulturverfahren und medium für das wachstum adhärenter tierzellen
DE69011622D1 (de) Verwendung von geschützten Aminosäuren in Futtermitteln für Schafe.
EP0348947A3 (en) Prevention or elimination of mycoplasma contamination of animal or plant cell culture
DE3774086D1 (de) Laktoferrin enthaltendes inkubationsmedium fuer festphasen-immunometrische verfahren und seine verwendung.
Marcus et al. Iron requirement for isolated rat liver mitochondrial protein synthesis
IL92529A0 (en) Generation of transgenic vertebrates by employing transformed sperm cells via artificial insemination
IT1244747B (it) Metodo per la fermentazione contemporanea di un amminoacido basico e di un amminoacido acido
GB9828624D0 (en) Production of proteins
Prather et al. Activation of porcine oocytes matured in vitro
Imada et al. Identification of 200,000-dalton human cell surface protein encoded by gene mapped to long arm of chromosome 11
UA8276A (uk) Спосіб виготовлення гама-інтерферонів та пристрій для його здійснення

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0481791

Country of ref document: EP

RZN Patent revoked